Mannkind MNKD Non Cash Contingent Consideration From Acquisition Of Sc Pharma
Non Cash Contingent Consideration From Acquisition Of Sc Pharma at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept mnkd:NonCashContingentConsiderationFromAcquisitionOfScPharma.
The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mannkind's non cash contingent consideration from acquisition of sc pharma.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mannkind's non cash contingent consideration from acquisition of sc pharma?
- Mannkind (MNKD) reported non cash contingent consideration from acquisition of sc pharma of $6.3M in Q4 2025.
- What does non cash contingent consideration from acquisition of sc pharma mean?
- Reflects the non-cash portion of purchase price adjustments related to earn-outs or performance-based milestones in a business acquisition. This represents future obligations that are settled through equity or other non-cash instruments rather than immediate cash outflows. It is a key indicator of the long-term valuation and risk profile associated with inorganic growth strategies.